NCT04744480

Brief Summary

The aim of the induction is to decrease stress response of endotracheal intubation. It is also important to keep hemodynamics stable during and after the induction period. Previous studies have shown that topical anesthesia can provide excellent superior supraglottic and subglottic local anesthetic effects and can significantly reduce the dosage of intravenous anesthetics. Therefore, it is significant to explore whether the combination of topical anesthesia and intravenous anesthetics could decrease the stress response of endotracheal intubation and keep hemodynamics stable during and after the induction period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P25-P50 for not_applicable coronary-artery-disease

Timeline
Completed

Started Mar 2021

Shorter than P25 for not_applicable coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2021

Completed
16 days until next milestone

First Posted

Study publicly available on registry

February 9, 2021

Completed
24 days until next milestone

Study Start

First participant enrolled

March 5, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 27, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2022

Completed
Last Updated

June 2, 2022

Status Verified

May 1, 2022

Enrollment Period

2 months

First QC Date

January 24, 2021

Last Update Submit

May 28, 2022

Conditions

Keywords

Topical anesthesiaCardiac surgeryHemodynamicsInduction period

Outcome Measures

Primary Outcomes (1)

  • The area under the curve of baseline blood pressure

    The area under the curve (AUC) of blood pressure below baseline from the beginning of general anesthesia induction to the surgery beginning.

    From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.

Secondary Outcomes (10)

  • The frequency and types of vasoactive drugs used.

    From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.

  • The incidence of arrhythmias.

    From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.

  • cardiac systolic function:Left Ventricular Ejection Fraction (LVEF)

    Preoperative, intraoperative

  • cardiac diastolic function:E/E' (the ratio of E peak and E') or E/A :(the ratio of E peak and A peak)

    Preoperative, intraoperative

  • cardiac output monitoring indicator: CO(cardiac output)

    Intraoperative

  • +5 more secondary outcomes

Study Arms (2)

The combined topical anesthesia induction group

EXPERIMENTAL

The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia,3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.

Procedure: The combined topical anesthesia induction group

The routine induction group

NO INTERVENTION

The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group,all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.

Interventions

The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia,3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.

The combined topical anesthesia induction group

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled to accept elective /major cardiac surgery;
  • Patients older than 18 years and younger than 85 years;
  • Patients of The American Society of Anesthesiologists ( ASA )Ⅱ - Ⅳ level grade;
  • Patients signed the informed consent form for the clinical study;

You may not qualify if:

  • Patients cannot cooperate to topical anesthesia;
  • Patients with a left cardiac assist device prior to surgery;
  • Patients with aortic dissection;
  • Patients with Intra Aortic Balloon Pump (IABP) prior to surgery;
  • Patients treated with Extracorporeal Membrane Oxygenation (ECMO) prior to surgery;
  • Patients with difficult airway;
  • Patients with high sensitivity and hypersensitivity to lidocaine and tetracaine;
  • Patients with atrioventricular block;
  • Hemoglobin(Hb)\<80g/L;
  • Patients who have participated in other clinical studies during the last 3 months;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meng-Lv

Jinan, Shandong, 250000, China

Location

Related Publications (1)

  • Chen TT, Lv M, Wang JH, Wei CS, Gu CP, Wang YL. Addition of topical airway anaesthesia to conventional induction techniques to reduce haemodynamic instability during the induction period in patients undergoing cardiac surgery: protocol for a randomised controlled study. BMJ Open. 2022 Jan 25;12(1):e053337. doi: 10.1136/bmjopen-2021-053337.

MeSH Terms

Conditions

Coronary Artery DiseaseHeart Valve DiseasesArrhythmias, CardiacCardiomyopathies

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Meng Lv, doctor

    Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 24, 2021

First Posted

February 9, 2021

Study Start

March 5, 2021

Primary Completion

April 27, 2021

Study Completion

April 27, 2022

Last Updated

June 2, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations